Should you buy these 3 healthcare shares?

Are CSL Limited (ASX:CSL), Fisher & Paykel Healthcare Corp Ltd (ASX:FPH), and Sirtex Medical Limited (ASX:SRX) an opportunity?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Good healthcare shares are almost always in high demand, with many investors perceiving that healthcare is both a defensive business and likely to see significant growth over the long term. Here's my take on whether these 3 well-known healthcare operators are a buy today:

CSL Limited (ASX: CSL)

CSL is a researcher and manufacturer of blood products for immune therapies and coagulation disorders, among others. It also owns a vaccine business, Seqirus, which has been unprofitable in recent times and is being turned around. CSL also has an extensive research pipeline of future treatments for things like heart attacks and sickle-cell disease. The only drawback is the price, as CSL's prospects are well known and it is commonly regarded as Australia's best company. If I knew I could take a 10-year time frame, I'd consider buying a small stake in CSL today, with the view to adding it on any price weakness.

Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)

Fisher & Paykel is a designer and manufacturer of oxygen masks and breathing apparatus; a booming industry in the USA, its major market. Although seemingly expensive, Fisher & Paykel is moving manufacturing to Mexico and building large factories to meet anticipated future demand. I'd consider taking a small stake in the company at today's prices, although a patent infringement lawsuit and counter-suit against ResMed Inc. (CHESS) (ASX: RMD) adds extra risk. Like CSL above, Fisher & Paykel is quite richly priced and I'd suggest buyers start with a small stake and a view to opportunistically increasing it over time.

Sirtex Medical Limited (ASX: SRX)

Sirtex shares have been hit hard by the failure of several important clinical trials, as well as the firing of former CEO Gilman Wong for improper share trading. The clinical trials mean that Sirtex is unlikely to expand the 'indications' (potential uses) for its SIR-Spheres treatment which ultimately means a smaller potential market. The new CEO has several ideas for cutting costs and growing sales in the current market, but were I not a shareholder already, I'd be inclined to wait on the fence while I see how it pans out.

Motley Fool contributor Sean O'Neill owns shares of Sirtex Medical Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »